Search

Displaying results 1871 - 1880 of 7671 in total
  1. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate ...

  2. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). … Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics.

  3. Drug

    Cenobamate

    go.drugbank.com/drugs/DB06119
    ApprovedInvestigational

    [L10653] Cenobamate was granted FDA approval on 21 November 2019.[L10653] … Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.

  4. Drug

    Idursulfase

    go.drugbank.com/drugs/DB01271
    ApprovedInvestigational

    Idursulfase is an enzyme that hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans dermatan sulfate and heparan sulfate in the lysosomes of various cell types

  5. Drug

    Modified vaccinia ankara

    go.drugbank.com/drugs/DB15483
    ApprovedInvestigational

    Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus.

  6. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026] … [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.

  7. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    [A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349] … [A235384] Ibrexafungerp is orally bioavailable compared to the echinocandins [caspofungin], [micafungin], and [anidulafungin]; which can only be administered parenterally.

    Synonyms: enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitor
  8. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012.

  9. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.

  10. Drug

    Methohexital

    go.drugbank.com/drugs/DB00474
    Approved

    An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.

    Synonyms: α-DL-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid